



03-02-07

Express Mail No.: EB 132 598 659 us
POWER OF ATTORNEY

1PW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Young et al.

Confirmation No.: 3135

Serial No.: 10/657,363

Art Unit: 1648

Filed: September 8, 2003

Examiner: Hill, Myron G.

For: ULTRA HIGH AFFINITY
NEUTRALIZING ANTIBODIESAttorney Docket No.: 10271-159-999
(Formerly: 469201-689)**REVOCATION AND POWER OF ATTORNEY**Commissioner for Patents
P.O.Box 1450
Alexandria, VA 22313-1450

Sir:

MedImmune, Inc. (applicant or assignee) hereby revokes any and all previous powers and appoints:

☒ Practitioners at Customer Number 20583

as his/her/its/their attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please direct all correspondence address for the above-identified application to:

☒ The above mentioned Customer Number.☒ Firm or Individual Name:Address: Jones Day, 222 East 41st Street, New York, New York 10017

Telephone: (212) 326-7832

We are the:



Applicant/Inventor

Assignee of record of the entire interest. See 37 CFR 3.71.
(Statement under 37 CFR 3.73(b) is applicable)

Statement Under 37 C.F.R. 3.73(b)

MedImmune, Inc. states that it is:

- ☒ the assignee of the entire right, title, and interest; or
☐ an assignee of less than the entire right, title and interest.
The extent (by, percentage) of its ownership interest is %

in the patent application/patent identified above by virtue of:

- ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: William Huse, Herren Wu, and Jeffry Watkins To: **Applied Molecular Evolution, Inc.** of parent application U.S. Serial No. **09/771,415**, of which the present application is a continuation. This document was recorded in the United States Patent and Trademark Office on **October 21, 2002** at Reel/Frame **013402/0257**.

2. From: James Young, Scott Koenig, and Leslie Johnson To: **MedImmune, Inc.** of parent application U.S. Serial No. **09/771,415**, of which the present application is a continuation. This document was recorded in the United States Patent and Trademark Office on **October 21, 2002** at Reel/Frame **013402/0673**.

3. From: **Applied Molecular Evolution, Inc** To: **MedImmune, Inc.**
In accordance with the terms of the Research and Assignment of February 24, 1999, by and between Ixsys, Inc. (now Applied Molecular Evolution, Inc.) and MedImmune, Inc., Applied Molecular Evolution, Inc. has sold, assigned, transferred and set over unto MedImmune, Inc. its entire right, title and interest in, to and under U.S. patent application Serial No. 10,657,363, entitled "Ultra High Affinity Neutralizing Antibodies," filed on September 8, 2003.

- ☐ Additional documents in the chain of title are listed on a supplemental sheet.
- ☐ Copies of assignments or other documents in the chain of title are attached.
[Note: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

ASSIGNEE: **MedImmune, Inc.**

Date:

26 Feb 2007

Signature:

William C. Bertrand, Jr.

Typed Name: **William C. Bertrand, Jr.**

Position/Title: **Sr. Vice President, General
Counsel & Compliance**

Note: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required.

- ☒ Total of one form is submitted.